Top 10 Companies in the Global Albendazole and Ivermectin Market (2026): Market Leaders Powering Global Health

MARKET INSIGHTS

Global Albendazole and Ivermectin market size was valued at USD 410 million in 2025 and is projected to grow from USD 430 million in 2026 to USD 610 million by 2034, exhibiting a CAGR of 5.2% during the forecast period.

Albendazole and Ivermectin are essential broad-spectrum anthelmintic and antiparasitic agents. Albendazole is a benzimidazole carbamate that works by selectively inhibiting tubulin polymerization, leading to the disruption of energy metabolism in parasitic worms. Ivermectin, a member of the avermectin family, acts by binding to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, causing paralysis and death of the parasite. These drugs are indispensable for controlling a wide range of nematode, cestode, and ectoparasite infestations in both livestock and humans.

The market’s steady expansion is primarily fueled by the persistent global burden of parasitic diseases, particularly in tropical and subtropical regions. The World Health Organization’s ongoing Mass Drug Administration (MDA) programs, which aim to control neglected tropical diseases like lymphatic filariasis and soil-transmitted helminthiases, represent a significant and consistent demand driver. In the veterinary sector, intensification of livestock production and the critical need to maintain herd health and productivity necessitate regular deworming protocols. However, the market faces headwinds from the growing issue of anthelmintic resistance, which is compelling the industry to invest in drug rotation strategies and combination therapies to maintain efficacy.

Global Albendazole and Lvermectin Market – View in Detailed Research Report

Top 10 Companies in the Global Albendazole and Ivermectin Market (2026)

🔟 1. Shandong Luxi Veterinary Pharmaceutical Co. Ltd

Headquarters: Shandong, China
Key Offering: Albendazole and Ivermectin powders, premixes, and oral solutions for livestock and human use

Shandong Luxi is one of the largest volume producers in the Asia‑Pacific region, supplying a steady and affordable supply of anthelmintics to both domestic and international markets. Their extensive distribution network ensures consistent availability for commercial farms and public health programs.

Sustainability Initiatives:

• Investing in green manufacturing practices to reduce carbon footprint
• Partnering with NGOs to support rural deworming campaigns
• Implementing waste‑reduction protocols in production facilities

9️⃣ 2. Shijiazhuang Shimu Pharmaceutical Co. Ltd

Headquarters: Hebei, China
Key Offering: Albendazole tablets, Ivermectin injectable formulations, and combination therapies

Shimu focuses on high‑quality formulations with stringent quality control, catering to both veterinary and human health sectors. Their products are widely used in mass drug administration programs across Asia.

Sustainability Initiatives:

• Adopting ISO 14001 environmental management systems
• Supporting community health education on parasite control
• Developing biodegradable packaging solutions

8️⃣ 3. Jinhe Biotechnology Co., Ltd

Headquarters: Henan, China
Key Offering: Advanced premix formulations for livestock deworming and human therapeutic tablets

Jinhe specializes in formulation technology that allows precise dosing in feed and water, enhancing compliance in large‑scale farming operations.

Sustainability Initiatives:

• Reducing energy consumption through process optimization
• Collaborating with local farmers to implement integrated parasite management
• Engaging in research on drug‑resistance mitigation

7️⃣ 4. Zhengzhou Yuxiang Agricultural Science and Technology Co. Ltd

Headquarters: Henan, China
Key Offering: Bulk powder formulations of Albendazole and Ivermectin for veterinary use

Yuxiang’s large‑scale production capacity supports high‑volume demand from commercial livestock farms, ensuring reliable supply chains.

Sustainability Initiatives:

• Implementing waste‑water recycling systems
• Partnering with government agencies for national deworming initiatives
• Investing in workforce training on sustainable farming practices

6️⃣ 5. Sichuan Hengtong Animal Protection Biotechnology Co. Ltd

Headquarters: Sichuan, China
Key Offering: Premium quality Ivermectin injectable solutions and oral formulations for livestock

Hengtong focuses on high‑purity APIs and strict regulatory compliance, making it a trusted supplier for large‑scale veterinary operations.

Sustainability Initiatives:

• Adhering to GMP and ISO 9001 standards
• Supporting local veterinary training programs
• Developing eco‑friendly packaging materials

5️⃣ 6. IMPERIA LIFESCIENCES PVT LTD

Headquarters: India
Key Offering: Innovative premix and powder formulations for both livestock and human markets

IMPERIA leverages advanced formulation technologies to deliver cost‑effective, high‑impact solutions in emerging economies.

Sustainability Initiatives:

• Implementing renewable energy in manufacturing plants
• Collaborating with NGOs to expand rural deworming coverage
• Investing in research on drug‑resistance markers

4️⃣ 7. Geevet Remedies

Headquarters: India
Key Offering: Pediatric‑friendly dispersible tablets and long‑acting injectable formulations

Geevet focuses on improving patient compliance, especially in children, and has a growing presence in community health programs.

Sustainability Initiatives:

• Using biodegradable excipients in tablet formulations
• Partnering with schools for health education
• Optimizing supply chains to reduce carbon emissions

3️⃣ 8. Shenzhen Pharma

Headquarters: Guangdong, China
Key Offering: Bulk powder and tablet formulations for veterinary and human use

Shenzhen Pharma provides high‑volume, cost‑effective anthelmintics, supporting national deworming initiatives across China.

Sustainability Initiatives:

• Adopting ISO 14001 environmental standards
• Supporting community outreach for parasite control
• Reducing packaging waste through recycled materials

2️⃣ 9. Zhejiang Pharmaceutical

Headquarters: Zhejiang, China
Key Offering: Albendazole and Ivermectin oral solutions and injectables for livestock

Zhejiang Pharmaceutical emphasizes product quality and regulatory compliance, catering to both domestic farms and export markets.

Sustainability Initiatives:

• Implementing energy‑efficient production lines
• Collaborating with local farms on integrated parasite management
• Investing in research on drug‑resistance mitigation

1️⃣ 10. Yunnan Animal Health

Headquarters: Yunnan, China
Key Offering: Combination therapies of Albendazole and Ivermectin for livestock and human use

Yunnan focuses on developing fixed‑dose combinations to enhance efficacy and reduce resistance development.

Sustainability Initiatives:

• Adhering to GMP and ISO 9001 standards
• Supporting rural health programs with free drug donations
• Investing in eco‑friendly manufacturing processes

Download FREE Sample Report: Global Albendazole and Lvermectin Market – View in Detailed Research Report

Get Full Report Here: Global Albendazole and Lvermectin Market – View in Detailed Research Report

🌍 Outlook: The Future of Albendazole and Ivermectin Market

The global Albendazole and Ivermectin market is poised for steady growth, driven by persistent parasitic disease burdens and expanding livestock production. Innovation in combination therapies, advanced formulations, and digital supply‑chain management will shape the next decade, while regulatory harmonization and resistance management remain critical focus areas.

📈 Key Trends Shaping the Market:

• Growing adoption of combination formulations to broaden spectrum and mitigate resistance.
• Shift toward powder‑based products for ease of administration in large‑scale livestock operations.
• Increasing regulatory scrutiny in North America and Europe, driving investment in quality and compliance.
• Expansion of deworming programs in emerging economies supported by public‑private partnerships.
• Emerging research on anti‑cancer and anti‑viral properties of Albendazole and Ivermectin, opening new therapeutic avenues.